Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Parallel track regulations

Executive Summary

National Institute of Allergy and Infectious Diseases' AIDS Research Advisory Committee emphasizes a "sincere desire for a definitive decision on the stalled parallel track initiative" in a Feb. 12 letter to NIAID Director Anthony Fauci, MD. The initiative would establish rules for NIAID's mechanism for expanded access to drugs still in clinical trials but has languished in the Office of Management and Budget for over a year. ARAC Chairman Gerald Medoff contended that parallel track "offers substantial improvements over the current ad hoc situation." The letter is expected to be sent to HHS' National AIDS Program Office.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS020496

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel